Fulcrum Therapeutics discontinued development of its sickle cell disease candidate pociredir after the FDA raised heightened concerns about risks and benefits. The company said the FDA concluded there was no viable regulatory path forward following an end-of-phase discussion in which Fulcrum referenced mechanistic differences from the PRC2 inhibitor class. Fulcrum’s decision follows Ipsen’s voluntary withdrawal of Tazverik (tazemetostat) in March after secondary blood cancer adverse events emerged in the SYMPHONY-1 trial. Fulcrum said it is now pursuing strategic alternatives, including potentially merging or selling assets or the business.